Dyadic International, Inc. headquartered in Jupiter (USA) has signed a collaboration agreement to commercialize second generation bio-fuel and bio-based chemical technology with Compagnie Industrielle de la Matière Végétale (“CIMV”) headquartered in Paris (France).
Dyadic is, a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bio-energy, bio-based chemical, biopharmaceutical and industrial enzyme industries. CIMV is among the pioneers in developing soft chemicals “Organosolv” type processes for the production of cellulosic sugars and very pure lignin from biomass fractionation.
CIMV’s patented approach of separating the three main components of plant material allows both production of high quality cellulose and hemi-cellulose, especially well-suited for the enzymatic process, and Biolignin™, a pure form of lignin that may be sold commercially as a high value, environmentally friendly alternative to petroleum-derived chemicals such as phenol. The technology has garnered industry acclaim in winning the Pierre Potier Prize for Innovation in Chemistry and Frost & Sullivan’s 2013 French Visionary Innovation Award.
Under the collaboration agreement, Dyadic and CIMV will work together to develop more efficient, fully integrated processes to produce environmentally low impact biofuels and bio-based chemicals. Dyadic anticipates supplying enzymes to CIMV’s planned 2015 demonstration plant, as well as, licensing its C1 technology for on-site production of enzymes at CIMV’s future commercial scale plants.
To complete the value chain from biomass to bioethanol, CIMV is also collaborating with Taurus Energy AB, a leading developer of yeast technology to turn cellulosic sugar into bioethanol, and for its international development with Pierson Capital, a leading developer of major infrastructure, transportation and energy programs in the emerging markets of China, Africa and Latin America.
Danai Brooks, Dyadic’s Chief Operating Officer, stated “We are excited to have yet another leading technology developer of second generation biofuels and bio-based chemicals recognize the power and performance of Dyadic’s C1 enzyme technology. Our C1 enzyme technology, coupled with CIMV’s biomass pretreatment technology and Pierson Capital’s established connections in emerging markets, can substantially broaden Dyadic’s footprint. Our scientists are working closely with CIMV scientists to tailor our C1 enzyme technology to CIMV’s high quality cellulose and hemi-cellulose, which we expect will significantly enhance our capabilities as an integrated technology offering.”
Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 expression system can also be used to screen for the discovery of novel genes.
Thiery Scholastique, CIMV’s Chief Executive Officer, added “We are very eager to partner with Dyadic. We are already collaborating together on Biolignin™ de-polymerization under the EU funded “Biomimetic” project. This new collaboration allows us to appreciate Dyadic’s technology and we have decided to extend our partnership on industrial sugars production activity. Together, we have demonstrated the ability to create high yields of fermentable sugars from our purer plant material using Dyadic’s CMAX™ enzymes. We believe that this collaboration will lead to more efficient and lower cost enzymes that can be produced onsite at CIMV’s commercial bio-refineries.”
The feedstock used in the CIMV process is non-food material and comes from agricultural byproducts (cereal straw, bagasse from sugarcane and sweet sorghum) or fiber crops (hemp, flax, Provence cane and miscanthus), but can also come from forestry residues. CIMV is involved in many European Program (Biocore, Biomimetic, Innobite, Reneseng). The Biocore program, ended in Feb 2014, recognized in its final report that’s the CIMV’s “Organosolv” bio-refining process can play a part in the future bioeconomy.